Allspring Global Investments Holdings LLC Has $56.46 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Allspring Global Investments Holdings LLC lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.9% during the fourth quarter, HoldingsChannel reports. The fund owned 1,824,127 shares of the company’s stock after selling 114,603 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Teva Pharmaceutical Industries were worth $56,457,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. raised its position in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 341,985 shares of the company’s stock valued at $10,673,000 after purchasing an additional 22,962 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $818,000. SeaCrest Wealth Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 16.6% in the fourth quarter. SeaCrest Wealth Management LLC now owns 53,865 shares of the company’s stock valued at $1,745,000 after buying an additional 7,680 shares during the period. Silverberg Bernstein Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 4.4% in the 4th quarter. Silverberg Bernstein Capital Management LLC now owns 95,317 shares of the company’s stock valued at $2,975,000 after buying an additional 4,000 shares during the last quarter. Finally, E. Ohman J or Asset Management AB bought a new position in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $614,000. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 14,150 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at $214,532.58. This trade represents a 67.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Richard D. Francis sold 442,935 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the sale, the chief executive officer directly owned 642,099 shares in the company, valued at $20,778,323.64. This trade represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 920,901 shares of company stock valued at $30,056,789 over the last three months. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $30.26 on Thursday. The stock has a market capitalization of $34.79 billion, a PE ratio of 25.21, a PEG ratio of 10.15 and a beta of 0.76. The business’s 50 day simple moving average is $32.22 and its 200 day simple moving average is $27.63. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on TEVA. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. The Goldman Sachs Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Scotiabank lifted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Piper Sandler reissued an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Finally, Barclays increased their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.